AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03904355
Drug: human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG triggering of ovulation
Trial: NCT02585479
Drug: Pirarubicin
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Pirarubicin 30mg/m2 intravenously~2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries
Trial: NCT02585479
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Oxaliplatin 100 mg/m2 intravenously~2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries
Trial: NCT02585479
Drug: Lipiodol
RxNorm normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol 5-10ml infused through the right and left hepatic arteries
Trial: NCT03770637
Drug: Glucagon RTU
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
Trial: NCT01687270
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
Trial: NCT03180190
Drug: Hydroxychloroquine Oral Tablet
RxNorm normalized name: hydroxychloroquine Oral Tablet
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)
Trial: NCT00547131
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00098384
Drug: rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01725672
Drug: Metformin, 500 mg extended release tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Trial: NCT01725672
Drug: Metformin, 1000 mg extended release tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Trial: NCT01725672
Drug: Glimepiride, 1 mg immediate release tablet
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Trial: NCT01725672
Drug: Glimepiride, 2 mg immediate release tablet
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Trial: NCT02597387
Drug: Mitoxantrone HCL Liposome Injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00676819
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00676819
Drug: human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01725672
Drug: Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Trial: NCT03229889
Drug: Cialis 5Mg Tablet
RxNorm normalized name: Cialis 5mg Tablet
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
Trial: NCT00354458
Drug: rolofylline
RxNorm normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rolofylline 30 mg IV QD; 3 days
Trial: NCT01725672
Drug: Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Trial: NCT01725672
Drug: Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Trial: NCT01725672
Drug: Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
Trial: NCT02865434
Drug: Tc99m-tilmanocept
RxNorm normalized name: technetium (99mTc) tilmanocept
DrugBank: Tilmanocept (DB15373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Trial: NCT00671788
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT01833676
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01833676
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01528709
Drug: Atorvastatin 80 mg daily
RxNorm normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 1 year
Trial: NCT01528709
Drug: Atorvastatin 10 mg daily
RxNorm normalized name: atorvastatin 10 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily for 1 year
Trial: NCT01237678
Drug: Carboplatin and Etoposide
RxNorm normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
Trial: NCT01314495
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept will be administrated as a 30 minute intravenous infusion.
Trial: NCT02930694
Drug: JNJ-54175446 (capsule)
RxNorm normalized name: JNJ-54175446
DrugBank: JNJ-54175446 (DB15358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
Trial: NCT02930694
Drug: JNJ-54175446 (suspension)
RxNorm normalized name: JNJ-54175446
DrugBank: JNJ-54175446 (DB15358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
Trial: NCT02145247
Drug: hCG
RxNorm normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4. Blood samples will be obtained at T = -0.5, 0, and +24 hours.
Trial: NCT03043053
Drug: oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxytocin intranasal spray
Trial: NCT00410358
Drug: Gimatecan
RxNorm normalized name: Gimatecan
DrugBank: Gimatecan (DB06721)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01832766
Drug: Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dronabinol 10 mg one capsule by mouth at 8:00 a.m.
Trial: NCT00469131
Drug: tacrolimus + steroid
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02530437
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02530437
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02530437
Drug: Taladegib
RxNorm normalized name: Taladegib
DrugBank: Taladegib (DB12550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01164761
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
Trial: NCT01164761
Drug: Altace
RxNorm normalized name: Altace
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
Trial: NCT02139540
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen \[inert\]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.
Trial: NCT01314495
Drug: Inactive infusion
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a 30 minute intravenous infusion.
Trial: NCT06195254
Drug: PD-1 blocking antibody
RxNorm normalized name: Humanized pd-1 blocking antibody hx-008
DrugBank: Pucotenlimab (DB17552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions and then received the treatment of PD-1 blockers including pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
Trial: NCT00176449
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg twice a day (starting with 150mg once a day for three days)
Trial: NCT00561054
Drug: CETUXIMAB
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg/m2 starting dose, 250 mg/m2 weekly dose
Trial: NCT02733393
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00396500
Drug: Albendazole (400 mg) and/or Vitamin a
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02460289
Drug: Treatment: Minoxidil 5% / Botanical Hair Solution for Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04294277
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At Day 1, prior to the start of treatment, results from screening visit evaluations are reviewed to determine eligibility requirements. Subsequent visits during treatment phase will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 weeks of therapy. Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease relapse or onset of unacceptable toxicity.
Trial: NCT02656160
Drug: Dalfampridine
RxNorm normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine 10 mg extended release 3 hrs before sleep
Trial: NCT00720499
Drug: BI 1744 CL plus tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
Trial: NCT01931384
Drug: Human chorionic gonadotrophin
RxNorm normalized name: Human chorionic gonadotrophin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
Trial: NCT00395577
Drug: VX-702
RxNorm normalized name: VX-702
DrugBank: VX-702 (DB05470)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00296517
Drug: 323U66 (Bupropion Hydrochloride Sustained Release)
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
Trial: NCT01700491
Drug: Epidural Catheter 0.2% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine into epidural space and saline into paravertebral space
Trial: NCT01700491
Drug: Paravertebral Catheter 0.4% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4% ropivacaine into paravertebral space and saline into the epidural space
Trial: NCT02308020
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT01005433
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
Trial: NCT02590809
Drug: Treatment BX1514M
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
Trial: NCT00914368
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
Trial: NCT01326871
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
Trial: NCT01326871
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
Trial: NCT01449253
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg initially and then increased to 20 mg TDS if there is no fall in BP
Trial: NCT01449253
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
Trial: NCT01570309
Drug: Ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule, 50,000 units, once a week, 12 weeks
Trial: NCT00322673
Drug: XL999
RxNorm normalized name: XL999
DrugBank: XL999 (DB05014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
Trial: NCT01677039
Drug: Test formulation administered with water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 20 mg of test formulation with 240 mL of water
Trial: NCT02893930
Drug: Sapanisertib
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02553941
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenous or subcutaneous
Trial: NCT02553941
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by mouth once daily
Trial: NCT00002569
Drug: lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002569
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002569
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00688961
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: generic aspirin
Trial: NCT04245774
Drug: Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
Trial: NCT04245774
Drug: Bupivacaine/Dextrose
RxNorm normalized name: BUPIVACAINE/DEXTROSE
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
Trial: NCT01518101
Drug: Vildagliptin/ Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
Trial: NCT01518101
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.2 mg once daily by commercially available injection pens
Trial: NCT01518101
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg tablets twice daily
Trial: NCT00037128
Drug: GL701
RxNorm normalized name: Glatiramer acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03513211
Drug: SUBA-itraconazole
RxNorm normalized name: ITRACONAZOLE COMPONENT OF SUBA-ITRACONAZOLE
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg PO BD
Trial: NCT03513211
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating doses in Rolling 6 Phase I
Trial: NCT02554396
Drug: PRX-100
RxNorm normalized name: PRX-03140
DrugBank: PRX-03140 (DB05596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT01944488
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 µg/m2 body surface max 100 µg i.v.
Trial: NCT00936793
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes